Wyeth Prempro Gets Dementia Warning; FDA Considering HRT Class Labeling
Executive Summary
FDA is considering hormone replacement therapy class labeling that would incorporate data from a WHI sub-study showing twice the rate of dementia in patients taking Wyeth's Prempro estrogen/progestin combo
You may also be interested in...
Prempro DTC Campaign Touts Lowest Approved Dose Of Hormone Therapy
Wyeth's direct-to-consumer advertising campaign for Prempro highlights the hormone replacement therapy's lowest dose approved by FDA
Prempro DTC Campaign Touts Lowest Approved Dose Of Hormone Therapy
Wyeth's direct-to-consumer advertising campaign for Prempro highlights the hormone replacement therapy's lowest dose approved by FDA
Premarin Memory Data Mixed On Dementia Risk; 91% Of Rxs For Menopause
Prescriptions for Wyeth's Prempro and Premarin have almost completely shifted to the relief of vasomotor symptoms in the two years since the first publication of negative findings from the Women's Health Initiative